Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.03%
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
2 Exciting Developments for Biogen Idec Inc.
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 17, 8:02AM CDT
Biogen , which just got nod from the FDA for its potential blockbuster hemophilia drug Eloctate last week, has also now cleared a major hurdle for a drug in its multiple sclerosis franchise. Joint developers Biogen and AbbVie announced Monday...
True North Therapeutics Announces $22 Million Series A Financing
Business Wire - Tue Jun 17, 6:00AM CDT
True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, announced today that it has completed a $22 million Series A equity financing. Proceeds from the financing will be used to advance True North's lead drug candidate, TNT009, into clinical development, with the initiation of the first human clinical trial planned for early 2015. The total Series A round encompasses initial funds from the spin-out of True North Therapeutics from iPierian, Inc., announced in September 2013. Investors in the Series A financing include Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures, and Baxter Ventures.
Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec
PR Newswire - Tue Jun 17, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec's expertise in neurology with Isis' leadership in antisense technology to develop novel therapies to treat neurological disorders and is the fourth collaboration between the two companies.
Our Drug Works! But There's a Catch ...
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 16, 5:21PM CDT
AFFiRiS' press release read like a monumental scientific discovery: Breakthrough in Alzheimer's disease: AFFiRiS halted clinical progression in Alzheimer patients upon treatment with AD04 in a phase II clinical study There's just one catch:...
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
Business Wire - Mon Jun 16, 6:30AM CDT
--a^' Positive Results Set Stage for Regulatory Filings -
Sobi to review preclinical data to potentially add future haemophilia A candidate to collaboration agreement with Biogen Idec
Thomson Reuters ONE - Mon Jun 16, 1:01AM CDT
On Friday, 13 June, Swedish Orphan Biovitrum AB's (publ) (Sobi) received a data package from Biogen Idec regarding a preclinical Hemophilia A program based on Amunix's proprietary XTEN technology. Amunix and Biogen Idec signed a worldwide license agreement in April 2014. Under the terms of Sobi and Biogen Idec's agreement, Sobi has the right to elect to obtain an option to add potential additional Factor VIII:Fc Constructs to the collaboration. Sobi has 120 days to review the preclinincal data, and to determine whether to elect to obtain such option under the collaboration. If Sobi elects to aquire its option, the company will be required to make a payment to Biogen Idec.
50-Day Moving Average Can Buffer A Strong Stock's Advance
at Investor's Business Daily - Fri Jun 13, 4:27PM CDT
It's frustrating to miss a heavy-volume breakout . The good thing is that the market likes to give second chances. If it's a truly a strong stock and the market is in a healthy uptrend, there will be plenty of other opportunities to buy it. The...
One Year Post-Launch, All Surveyed U.S. Neurologists Report Having Clinical Experience with Biogen Idec's Tecfidera for the Treatment of Multiple Sclerosis
PR Newswire - Thu Jun 12, 11:00AM CDT
Decision Resources Group finds that, within one year of commercial availability, 100 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their multiple sclerosis (MS) patients, far surpassing the one-year trial rate for Genzyme's Aubagio (69 percent) and Novartis's Gilenya (79 percent), despite the fact that Tecfidera is the third-to-market oral disease-modifying therapy (DMT) for MS. Driven by significant increases wave over wave, neurologist-reported Tecfidera patient share among DMT-treated relapsing-remitting MS (RR-MS) patients has grown to 13 percent and now exceeds that reported for Aubagio and Gilenya combined. Among high Tecfidera prescribers, Tecfidera is anticipated to become the RR-MS patient share leader as it will overtake Teva's Copaxone within the next six months.
3 Reasons to Watch Array Biopharma Inc.
Nathaniel Calloway, The Motley Fool - Motley Fool - Thu Jun 12, 9:56AM CDT
It is no secret that the risks associated with pharmaceutical development are considerable. The cost to develop a novel drug often exceeds $1 billion. Many smaller biotechs support these high development costs by by offering licensing options to...
Watch for Biogen Idec to Potentially Rebound After Falling 1.50% Yesterday
Comtex SmarTrend(R) - Wed Jun 11, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $308.00 to a high of $314.99. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $312.61 on volume of 884,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful
FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - Wed Jun 11, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.
RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology
Business Wire - Wed Jun 11, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.
Why the Future Is Bright for Isis Pharmaceuticals
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 5:30PM CDT
Isis Pharmaceuticals shares have surged this past week on news that it has received two milestone payments for advancing new drugs into phase 1 trials. Those milestone payments from Biogen and AstraZeneca successfully shifted attention away...
Up 37%: Can Receptos Compete With Novartis?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 10, 5:15PM CDT
Receptos shareholders had a great day today, with the stock up 37% on exciting phase 2 data for its lead drug candidate RPC1063 in multiple sclerosis. And with a phase 3 trial pitting RPC1063 against Biogen Idec 's Avonex ongoing, there is some...
Can Receptos' New Drug Beat Biogen?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
Receptos shares surged by a 36% this morning following news that the company's RPC1063 met its primary endpoint as a treatment for relapsing multiple sclerosis. The midstage trial results offer investors hope that Receptos' product will...
Isis Pharma Earns Milestone Payment on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 10:30AM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a milestone payment of $14 million from Biogen with the initiation of a phase I study on ISIS-DMPKRx for the treatment of myotonic dystrophy type I (DM1).